Excellent results for another ADC in this case targeting NaPi2B !! PROC patients achieved an outstanding ORR 59%!! Congrats to Dr Gonzalez por excellent presentation in ESMO - Eur. Oncology GEICO-Spanish Gynaecological Cancer Research Group

NaPi2b still a valuable target for ADC after the results of TUB040 in the NAPISTAR trial in ESMO - Eur. Oncology #ESMO25 GEICO-Spanish Gynaecological Cancer Research Group

Really enjoyed the excellent and intelligent discussion by Dr Kristina Lindemann Kristina Lindemann in #ESMO25 ESMO - Eur. Oncology

See the talent we have in GEICO-Spanish Gynaecological Cancer Research Group Drs Gonzalez and Oaknin are now discussing in oral session of #ESMO25 ESMO - Eur. Oncology Don t miss Dr Barretina in the preferred session later!!

Relacorilant is very active in PROC patients progressing while on PARPi !!! The combination relacorilant+nabpaclitaxel covers an unmet need according to this sub analysis of the ROSELLA trial !!! Amazing results and amazing presentation by Dr Lorusso Domenica lorusso in #ESMO25

Only a word to define the discussion of Dr Van Gorp in #esmo25 in mini oral session gyne. Brilliant!

Outstanding presentation of Dr Barretina Pilar Barretina . in the proffered oral communication in ESMO - Eur. Oncology #ESMO25 !!! Unfortunately OS data were not positive in the Attend trial for all comers but OS in MMRD is outstanding

Diversity matters!!! Reporting of race and ethnicity is a must in clinical trials!! Results of the Attend trial showed no benefit in OS in Asian patients vs non-Asian in advanced endometrial cancer. Don’t miss the presentation by Dr Barretina Pilar Barretina from GEICO-Spanish Gynaecological Cancer Research Group

Dr Lorusso discussing Attend trial. Asian race could be one of the potential confounding factors to explain differences in OS data in RCTs in endometrial cancer. Be diverse in your inclusion criteria and Report diversity!!! ESMO - Eur. Oncology #esmo2025

Dr Barretina Pilar Barretina discussing OS data from Attend trial. Outstanding contribution of Geico group GEICO-Spanish Gynaecological Cancer Research Group

A Chinese study in ovarian cancer found superiority of fuzuloparib and fuzuloparib+apstinib vs placebo. However no clear impact of the combination vs single agent PARPi fuzuloparib ESMO - Eur. Oncology

Impressive impact on OS by carbo-weekly pacli +bev vs same regimen but with three-weekly paclitaxel!!! This is going to be very provocative!! Don’t miss this communication. Fantastic prrsentation by Dr Clamp of the ICON8b in ESMO - Eur. Oncology #esmo2025

We have the third ADC today hitting the threshold of more than 50% ORR in an early trial in PROC today in #ESMO25 ESMO - Eur. Oncology. Raludotatug deruxtecan is in fact active in PROC regardless CDH6 expression. Outstanding presentation by Isabelle Ray-Coquard

Rejoice trial showed an outstanding activity of radulotatug deruxtecan in PROC in ESMO - Eur. Oncology #ESMO25 !!! Don’t miss the presentation by Isabelle Ray-Coquard

📸 Finalizamos unos días intensos de ciencia, reencuentros e inspiración. En #ESMO25, hemos tenido la oportunidad de compartir el trabajo de todo un equipo comprometido con la investigación clínica y traslacional en cáncer ginecológico. Gracias a quienes habéis seguido nuestras

Many practice-changing studies were presented at this year’s ESMO. Alongside them, several “negative” trials too. To all patients who took part in these studies, heartfelt thank you. Better cancer care is still ahead, and your courage lights the way. Teresa Amaral, MD, PhD

#IGCS Congratulations Dr Makker- sustained improvement with selinexor across endpoints! Excited for XPORT study to be completed 🤩

🔬 SEOM entrega 70 Becas, Proyectos y Premios, con una dotación de más de 1.300.000 euros a oncólogos médicos, la cifra más alta de su historia, para formación e investigación clínica en cáncer en 2025: 4️⃣ Estancias en el extranjero. 1️⃣2️⃣ Bolsas de viaje SEOM para rotaciones

Continuamos en #SEOM25 con la Sesión Ginecológico II. En ella ha tenido lugar la mesa de Controversias en Cáncer Ginecológico, moderada por la Dra. Pilar Barretina y el Dr. Antonio González. En la primera parte, el Dr. Alejandro Pérez-Fidalgo y la Dra. Lydia Gaba han debatido

Orgulloso de recibir la beca SEOM 2025 en cáncer ginecológico !!!